庄春林

个人简历

2009年毕业于南京医科大学药学本科，2014年毕业于第二军医大学药物化学专业，获得博士学位，2012-2013年美国明尼苏达大学药物化学系联合培养博士。现任海军军医大学hg8868官网副院长、教授、博导。兼任中国药学会科技开发与医药信息工作委员会委员、上海市药学会药物化学专业委员会委员、《Acta Pharmaceutica Sinica B》、《Chinese Chemical Letters》等6本国内外期刊编委。入选国家重点研发青年首席科学家、国家“优青”、中国科协青年人才托举工程、上海市曙光学者、晨光学者、上海市卫生系统优秀青年人才等。获中国药学会科技一等奖、中国药学会-施维雅青年药物化学奖、上海市药学科技一等奖、国家海洋科学技术一等奖、全军优秀博士论文奖等。

承担科研课题

1. 科技部, 国家重点研发计划青年科学家项目, 2021YFA1302200, 基于小分子调控的泛素化修饰在坏死性炎症中的作用和干预策略研究, 2021-12 至 2026-11, 500万元, 主持

2. 国家自然科学基金委员会, 优秀青年科学基金项目, 82022065, 药物化学, 2021-01-01 至 2023-12-31, 150万元,主持

3. 上海市教委, 曙光计划，21SG38，程序性细胞坏死药物化学研究，2021-10至 2024-12，15万元, 主持

4. 上海市科委, 生物医药项目, 21S11900800, 海洋共附生真菌来源的程序性细胞坏死抑制剂ZC80靶点研究, 2021-08 至 2024-07, 20万元, 主持

近五年代表性论文、专著

1.      Sun Y, Xu L, Zheng D, Wang J, Liu G, Mo Z, Liu C, Zhang W, Yu J, Xing C, He L*, Zhuang C*. A potent phosphodiester Keap1-Nrf2 protein-protein interaction inhibitor as the efficient treatment of Alzheimer's disease. Redox Biology, 2023: 102793. (IF=11.4)

2.      Yan J, Li Y, Ding L, Hou R, Xing C, Jiang C*, Miao Z*, Zhuang C*. Fragment-Based Discovery of Azocyclic Alkyl Naphthalenesulfonamides as Keap1-Nrf2 Inhibitors for Acute Lung Injury Treatment. Journal of Medicinal Chemistry, 2023 May 31;66(12):8267-8280. (IF=7.3)

3.      Xu L, Zhuang C*. Profiling of small-molecule necroptosis inhibitors based on the subpockets of kinase-ligand interactions. Medicinal Research Reviews 2023 Nov;43(6):1974-2024. (IF=13.3)

4.      Zhang X, Han Q, Hou R, Xu L, Zhang W, Xing C, Xue L*, Zhuang C*. Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway. Journal of Medicinal Chemistry 2023 Apr 13;66(7):5261-5278. (Cover story, IF=7.3)

5.      Quan D, Hou R, Shao H, Zhang X, Yu J, Zhang W, Yuan H*, Zhuang C*. Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets. Journal of Medicinal Chemistry 2023 Feb 23;66(4):3073-3087. (IF=7.3)

6.      Sun Y, Xu L, Shao H, Quan D, Mo Z, Wang J, Zhang W, Yu J, Zhuang C*, Xu K*. Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor- Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer's Disease. Journal of Medicinal Chemistry 2022 Nov 10;65(21):14957-14969. (Cover story, IF=7.3)

7.      Li J, Cai Z, Li XW*, Zhuang C*. Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives. Journal of Medicinal Chemistry 2022 Oct 27;65(20):13533-13560. (IF=7.3)

8.      Liu G, Hou R, Xu L, Zhang X, Yan J, Xing C, Xu K*, Zhuang C*. Crystallography-Guided Optimizations of the Keap1-Nrf2 Inhibitors on the Solvent Exposed Region: From Symmetric to Asymmetric Naphthalenesulfonamides. Journal of Medicinal Chemistry 2022 Jun 23;65(12):8289-8302. (Cover story, IF=7.3)

9.      Zhu J, Xin M, Xu C, He Y, Zhang W, Wang Z*, Zhuang C*. Ligand-based substituent-anchoring design of selective receptor-interacting protein kinase 1 necroptosis inhibitors for ulcerative colitis therapy. Acta Pharmaceutica Sinica B 2021 Oct;11(10):3193-3205. (IF=14.5)

10.  Zhang H, Xu L, Qin X, Chen X, Cong H, Hu L, Chen L, Miao Z, Zhang W*, Cai Z*, Zhuang C*. N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy) benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships and In Vivo Efficacy. Journal of Medicinal Chemistry 2019, 62(14): 6665-6681. (Cover story, IF=7.3)